{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:47:39Z","timestamp":1782384459188,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00439-6","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:48:32Z","timestamp":1779302912000},"page":"767-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cocuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariafiorella","family":"Brangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cartabellotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree Lucy Anna Rita","family":"Caudullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovan Giuseppe","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Gruttadauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Pacella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schiad\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Silletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca Svegliati","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Assanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deligios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Lodolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Russello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the M. D. T. Project Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"439_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"439_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"key":"439_CR3","unstructured":"AIOM. I NUMERI DEL CANCRO IN ITALIA 2023. 2023."},{"key":"439_CR4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23485","volume":"51","author":"G Cabibbo","year":"2010","unstructured":"Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274\u201383. https:\/\/doi.org\/10.1002\/hep.23485.","journal-title":"Hepatology"},{"key":"439_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/HEP.0000000000000527","volume":"79","author":"M Iavarone","year":"2024","unstructured":"Iavarone M, Nault J-C, Cabibbo G, et al. Indolent cancer and pattern of progression: two missing parameters in trial design for hepatology. Hepatology. 2024;79:1452\u201362. https:\/\/doi.org\/10.1097\/HEP.0000000000000527.","journal-title":"Hepatology"},{"key":"439_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","volume":"80","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo G, Celsa C, Rimassa L, et al. Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice. J Hepatol. 2024;80:957\u201366. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.018.","journal-title":"J Hepatol"},{"key":"439_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet"},{"key":"439_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/liv.13242","volume":"37","author":"A Pecorelli","year":"2017","unstructured":"Pecorelli A, Lenzi B, Gramenzi A, et al. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver Int. 2017;37:423\u201333. https:\/\/doi.org\/10.1111\/liv.13242.","journal-title":"Liver Int"},{"key":"439_CR9","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","volume":"24","author":"A Vitale","year":"2023","unstructured":"Vitale A, Cabibbo G, Iavarone M, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22. https:\/\/doi.org\/10.1016\/S1470-2045(23)00186-9.","journal-title":"Lancet Oncol"},{"key":"439_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/liv.14154","volume":"39","author":"A Vitale","year":"2019","unstructured":"Vitale A, Farinati F, Pawlik TM, et al. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. Liver Int. 2019;39:1478\u201389. https:\/\/doi.org\/10.1111\/liv.14154.","journal-title":"Liver Int"},{"key":"439_CR11","unstructured":"Linee Guida Epatocarcinoma. AIOM 2020. https:\/\/www.aiom.it\/linee-guida-aiom-2020-epatocarcinoma\/."},{"key":"439_CR12","unstructured":"ISS. Linee Guida inter-societarie Epatocarcinoma: Gestione multidisciplinare del paziente con epatocarcinoma 2023."},{"key":"439_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.dld.2023.10.029","volume":"56","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) \u2013 Part I - surgical treatments. Dig Liver Dis. 2024;56:223\u201334. https:\/\/doi.org\/10.1016\/j.dld.2023.10.029.","journal-title":"Dig Liver Dis"},{"key":"439_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.dld.2023.10.028","volume":"56","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) \u2013 Part II \u2013 non-surgical treatments. Dig Liver Dis. 2024;56:394\u2013405. https:\/\/doi.org\/10.1016\/j.dld.2023.10.028.","journal-title":"Dig Liver Dis"},{"key":"439_CR15","unstructured":"SQUIRE | SQUIRE 2.0 Guidelines n.d. https:\/\/www.squire-statement.org\/index.cfm?fuseaction=page.viewPage&pageID=471&nodeID=1."},{"key":"439_CR16","unstructured":"Societ\u00e0 italiana di gastroenterologia ed endoscopia digestiva n.d. https:\/\/www.sigeitalia.it\/ (accessed December 11, 2025)."},{"key":"439_CR17","unstructured":"AISF - Assoc Ital Studio FEGATO n.d. https:\/\/www.webaisf.org\/en\/homepage-ing\/."},{"key":"439_CR18","unstructured":"Redefining health care: creating value-based competition on results. 2006."},{"key":"439_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S0140-6736(13)61047-8","volume":"382","author":"JY Kim","year":"2013","unstructured":"Kim JY, Farmer P, Porter ME. Redefining global health-care delivery. Lancet. 2013;382:1060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)61047-8.","journal-title":"Lancet"},{"issue":"aug13 1","key":"439_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4078","volume":"341","author":"TM Trebble","year":"2010","unstructured":"Trebble TM, Hansi N, Hydes T, et al. Process mapping the patient journey: an introduction. BMJ. 2010;c4078. https:\/\/doi.org\/10.1136\/bmj.c4078.","journal-title":"BMJ"},{"key":"439_CR21","unstructured":"PNE - Programma Nazionale Esiti n.d. https:\/\/pne.agenas.it\/home."},{"key":"439_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/mi11030291","volume":"11","author":"S Graziadio","year":"2020","unstructured":"Graziadio S, Winter A, Lendrem BC, et al. How to ease the pain of taking a diagnostic point of care test to the market: a framework for evidence development. Micromachines. 2020;11:291. https:\/\/doi.org\/10.3390\/mi11030291.","journal-title":"Micromachines"},{"key":"439_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180398","volume":"12","author":"D Seys","year":"2017","unstructured":"Seys D, Bruyneel L, Deneckere S, et al. Better organized care via care pathways: a multicenter study. PLoS One. 2017;12:e0180398. https:\/\/doi.org\/10.1371\/journal.pone.0180398.","journal-title":"PLoS One"},{"key":"439_CR24","unstructured":"Banche dati. Accredia n.d. https:\/\/www.accredia.it\/banche-dati\/."},{"key":"439_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/liv.14735","volume":"41","author":"F Garuti","year":"2021","unstructured":"Garuti F, Neri A, Avanzato F, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41:585\u201397. https:\/\/doi.org\/10.1111\/liv.14735.","journal-title":"Liver Int"},{"key":"439_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.seminoncol.2012.05.006","volume":"39","author":"G Cabibbo","year":"2012","unstructured":"Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374\u201383. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.05.006.","journal-title":"Semin Oncol"},{"key":"439_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.dld.2015.01.001","volume":"47","author":"A Mancuso","year":"2015","unstructured":"Mancuso A, Mazzola A, Cabibbo G, et al. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis. 2015;47:324\u201330. https:\/\/doi.org\/10.1016\/j.dld.2015.01.001.","journal-title":"Dig Liver Dis"},{"key":"439_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","volume":"67","author":"G Cabibbo","year":"2017","unstructured":"Cabibbo G, Petta S, Barbara M, et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017;67:65\u201371. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.033.","journal-title":"J Hepatol"},{"key":"439_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","volume":"81","author":"C Celsa","year":"2025","unstructured":"Celsa C, Cabibbo G, Fulgenzi CAM, et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment. Hepatol Baltim Md. 2025;81:837\u201352. https:\/\/doi.org\/10.1097\/HEP.0000000000001026.","journal-title":"Hepatol Baltim Md"},{"key":"439_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","volume":"31","author":"G Cabibbo","year":"2025","unstructured":"Cabibbo G, Celsa C, Battaglia S, et al. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death. Clin Cancer Res. 2025;31:543\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2582.","journal-title":"Clin Cancer Res"},{"key":"439_CR31","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology"},{"key":"439_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000503603","volume":"14","author":"L Biganzoli","year":"2019","unstructured":"Biganzoli L, Marotti L, Cardoso M-J, et al. European guidelines on the organisation of breast centres and voluntary certification processes. Breast Care Basel. 2019;14:359\u201365. https:\/\/doi.org\/10.1159\/000503603.","journal-title":"Breast Care Basel"},{"key":"439_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamaoncol.2023.6811","volume":"10","author":"P Erfani","year":"2024","unstructured":"Erfani P, Uppal N, Lam MB. Accreditation standards\u2014An untapped lever for cancer equity. JAMA Oncol. 2024;10:429\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6811.","journal-title":"JAMA Oncol"},{"key":"439_CR34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.6004\/jnccn.2020.7689","volume":"19","author":"A Rao","year":"2021","unstructured":"Rao A, Rich NE, Marrero JA, et al. Diagnostic and therapeutic delays in patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2021;19:1063\u201371. https:\/\/doi.org\/10.6004\/jnccn.2020.7689.","journal-title":"J Natl Compr Canc Netw"},{"key":"439_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/liv.15180","volume":"42","author":"E Mauro","year":"2022","unstructured":"Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int. 2022;42:488\u201391. https:\/\/doi.org\/10.1111\/liv.15180.","journal-title":"Liver Int"},{"key":"439_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1586\/egh.11.105","volume":"6","author":"RG Gish","year":"2012","unstructured":"Gish RG, Lencioni R, Di Bisceglie AM, et al. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2012;6:173\u201385. https:\/\/doi.org\/10.1586\/egh.11.105.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"439_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.36401\/JQSH-23-22","volume":"7","author":"KA Abuelgasim","year":"2024","unstructured":"Abuelgasim KA, Jazieh AR. Quality measures for multidisciplinary tumor boards and their role in improving cancer care. Glob J Qual Saf Healthc. 2024;7:28\u201333.","journal-title":"Glob J Qual Saf Healthc"},{"key":"439_CR38","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/liv.15898","volume":"44","author":"A Colli","year":"2024","unstructured":"Colli A, Prati D. Against multidisciplinarity: more is not necessarily better. Liver Int. 2024;44:1278\u201380. https:\/\/doi.org\/10.1111\/liv.15898.","journal-title":"Liver Int"},{"key":"439_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102041","volume":"49","author":"M Ahmed","year":"2024","unstructured":"Ahmed M, Shafiq A, Zahid M, et al. Clinical outcomes with nurse-coordinated multidisciplinary care in patients with heart failure: a systematic review and meta-analysis. Curr Probl Cardiol. 2024;49:102041. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102041.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"439_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12913-022-07467-8","volume":"22","author":"C Willmington","year":"2022","unstructured":"Willmington C, Belardi P, Murante AM, et al. The contribution of benchmarking to quality improvement in healthcare. A systematic literature review. BMC Health Serv Res. 2022;22:139.","journal-title":"BMC Health Serv Res"},{"key":"439_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2018-000436","author":"A Jazieh","year":"2019","unstructured":"Jazieh A, Alkaiyat MO, Ali Y, et al. Improving adherence to lung cancer guidelines: a quality improvement project that uses chart review, audit and feedback approach. BMJ Open Qual. 2019. https:\/\/doi.org\/10.1136\/bmjoq-2018-000436.","journal-title":"BMJ Open Qual"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00439-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:54:04Z","timestamp":1782381244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00439-6","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Cabibbo participated in advisory boards and received speaker fees from Bayer, Eisai, Ipsen, MSD, AstraZeneca, Roche, and Gilead. Ciro Celsa received speaker fees from Eisai, Ipsen, MSD, and AstraZeneca and travel support from Roche. Rossana Berardi has financial interests with AstraZeneca (advisory board), Bayer (advisory board), Boehringer Ingelheim (advisory board), EISAI (advisory board), Gilead (Invited Speaker), Incyte (advisory board), Eli Lilly (advisory board), Menarini (advisory board), Merck (advisory board), and MSD (advisory board); institutional funding was received from AstraZeneca, Pfizer, and Roche. Rossana Berardi is an Editorial Board member of\n                      Oncology and Therapy\n                      ; she was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions. Roberto Bordonaro received fees from Bayer, AstraZeneca, Novartis, Amgen, Roche, Pfizer, Janssen Cilag, and Bristol Myers Squibb. Giovanni Galati received speaker fees from EISAI and speaker fees and congress travel support from Roche. Marianna Silletta received speaker fees and travel grants from Eisai, Roche, and AstraZeneca. Giuseppina Pacella received fees from AstraZeneca and Terumo. Bruno Daniele received fees from Roche, Bristol Myers Squibb, AstraZeneca, EISAI, MSD, and Incyte. Martina Assanti, Francesco Deligios, Giada Lodolo, and Luca Pinto are employees of IQVIA Solutions Italy S.r.l.; IQVIA received professional service fees from AstraZeneca Italy S.p.a. Caterina Cocuzza, Maria Rosaria Attanasio, Antonio Avallone, Fabio Cartabellotta, Desiree Lucy Anna Rita Caudullo, Giovan Giuseppe Di Costanzo, Mariafiorella Brangi, Piera Federico, Salvatore Gruttadauria, Francesco Izzo, Anna Nappi, Mauro Piccirillo, Ferdinando Riccardi, Laura Schiad\u00e0, Marta Schirripa, Gianluca Svegliati Baroni, Emiliano Tamburini, Raffaella Tortora, and Maurizio Russello declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study focused exclusively on organizational processes and the perspectives of healthcare professionals. All participants were members of the MDT Project working group, whose involvement was formally established through a collaboration agreement between IQVIA and each hospital's general management. Participants were informed that findings would be disseminated through scientific publications. As the project did not collect patient-level data or personal health information but focused exclusively on organizational processes and professionals\u2019 perspectives, participating institutions deemed ethics approval not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}